Heparanase-neutralizing monoclonal antibodies
US11161912B2 · kind B2 · utility
0Cited by
3References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 13, 2016 |
| Grant date | Nov 2, 2021 |
| Priority date | — |
| Expiry date | Mar 30, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to heparanase-neutralizing monoclonal antibodies (m Abs), pharmaceutical composition comprising same, and use thereof for treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, diabetes and related complications. The present invention further provides combined therapies comprising the heparanase-neutralizing m Ab and an anti-cancer treatment such as chemotherapy or radiation, for treating a proliferative disease in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.